ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in the following investor conferences:

• Guggenheim Inaugural Healthcare Innovation Conference (Boston, MA)Monday, November 11, 2024Fireside Chat at 11:30 a.m. Eastern Time

• UBS Global Healthcare Conference (Rancho Palos Verdes, CA)Wednesday, November 13, 2024Available for 1x1 meetingsFireside Chat at 9:30 a.m. Pacific Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: 240-654-1450ir@altimmune.com

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

Investor Contacts:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

This press release was published by a CLEAR® Verified individual.